IVI and Finland
On 26 June 2020, The Parliament of Finland ratified the IVI Establishment Agreement.
On 8 July 2020, Finland deposited an instrument of accession to the IVI Establishment Agreement with the United Nations.
Finnish Leadership at IVI
Dr. Outi Kuivasniemi, Deputy Director for International Affairs at the Ministry of Social Affairs and Health Republic of Finland. (2020- Present)
Finland contributes €500,000 Euros annually to IVI in non-earmarked core budget support in order to facilitate the advancement of the UN Sustainable Development Goals and Finland’s development policy. Finland’s contribution advances the development of vaccines for neglected diseases, which play a key role in eradicating poverty, reducing inequality, improving the health of women and girls, strengthening healthcare systems, and recuing the impact of climate change in low- and middle-income countries.
As part of Finland’s COVID-19 response, the government of Finland provided IVI an additional €500,000 Euros to support development of COVID-19 vaccines with Finnish partners.
COVID-19 Vaccine Development
IVI works with the Finnish Institute for Health and Welfare (THL) and University of Helsinki on COVID-19 vaccine development.
The overall objective of this project is to develop the basic production/testing processes for an IVI liposomal-based adjuvant system (ILA) to be used in conjunction with alum-adjuvanted formulations (ILAA) and/or QS-21 (ILAQ), compare it with the material received from WRAIR though CRADA and/or research-use agreements as appropriate through testing/characterization, evaluate this adjuvant system in formulations with COVID-19 antigens against those using same antigens and different adjuvants in small animals to identify possible vaccine candidates for further clinical development